A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial
Lynch, David R., Willi, Steven M., Wilson, Robert B., Cotticelli, M. Grazia, Brigatti, Karlla W., Deutsch, Eric C., Kucheruk, Olena, Shrader, William, Rioux, Patrice, Miller, Guy, Hawi, Amale, Sciascia, Thomas
Published in Movement disorders (01.07.2012)
Published in Movement disorders (01.07.2012)
Get full text
Journal Article
A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis
Eudy‐Byrne, Rena, Riggs, Matthew, Hawi, Amale, Sciascia, Thomas, Rohatagi, Shashank
Published in British journal of clinical pharmacology (01.07.2023)
Published in British journal of clinical pharmacology (01.07.2023)
Get full text
Journal Article
43271 Patient-Reported Outcomes From the Randomized Phase 2b/3 PRISM Trial Evaluating Oral Nalbuphine Extended-Release Versus Placebo in Patients With Prurigo Nodularis
Ständer, Sonja, Weisshaar, Elke, Parish, Jennifer L., Szepietowski, Jacek C., Reich, Adam, Korman, Neil J., Bortey, Enoch, Sciascia, Thomas R.
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
25853 Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase
Weisshaar, Elke, Szepietowski, Jacek C., Sciascia, Thomas R., Yosipovitch, Gil, Ständer, Sonja
Published in Journal of the American Academy of Dermatology (01.09.2021)
Published in Journal of the American Academy of Dermatology (01.09.2021)
Get full text
Journal Article